stockrow
Saturday 7 November 2026
Export JBIO’s income statement to Excel — free account
Jade Biosciences, Inc.
JBIO Healthcare Biotechnology
- EPS
- +11.6%
- Free cash flow
- −115.1%
Quarter to June 2026, against a year earlier
15.03
0.93
+6.60%
Follow JBIO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (46.16%) | (66.98%) | (85.55%) | (96.67%) |
+8 more TTM periods Free account |
|
| (42.54%) | (62.68%) | (57.84%) | (85.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(33.66%) | (41.98%) | (36.76%) | (70.09%) | |
Free Cash Flow per Share |
(2.02) | (1.73) | (3.03) | (1.95) | |
Free Cash Flow |
(123.51) | (100.01) | (94.95) | (77.14) | |
Capital Expenditures |
— | — | (0.26) | (0.29) | |
| Other line items | |||||
Cash ROIC |
(13.71%) | (16.46%) | (14.20%) | (20.39%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.80 | 0.77 | 0.61 | |
Depreciation/Fixed assets |
(11.08) | (7.91) | (5.76) | (13.32) | |
Capex/Depreciation |
0.00 | 0.00 | 0.27 | 0.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.02) | (1.73) | (3.02) | (1.94) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026